Goldman Sachs resumed coverage of Halozyme (HALO) with a Neutral rating and $55 price target The firm expects the hares to be range-bound until there is greater regulatory clarity.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Closing Bell Movers: Progress Software slips 4% after earnings
- Halozyme added to Russell 1000 Index
- Halozyme says Argenx received EU approval for Vyvgart with Enhanze for CIDP
- PGR institution likely weakens Halozyme bull case scenario, says Wells Fargo
- Merck granted review of Halozyme patent claims by PTAB